박셀바이오

323990KOSDAQ자연과학 및 공학 연구개발업

56.3 / 100

Reference Date: 2026-06-10

Financial Score21.0 / 40

News Sentiment21.3 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but Operating Profit is on a declining trend. Plunged 29.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Parkcell Bio is a biotech company specializing in cancer immunotherapy, developing various platforms such as Vax-NK and Vax-CAR for immune cell therapies and targeted anticancer drugs. It also expands its pet healthcare business through its veterinary immunomodulatory drug 'Vaxleukin-15' and has enhanced its commercialization capabilities by constructing an advanced manufacturing platform following the completion of its new headquarters in 2025.

Number of Employees

91people

Average Salary

49.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

1.88Industry Average 3.245.5Point

Lower than industry avg (good)

ROE

-20.04Industry Average -32.093.5Point

Below industry avg

Debt Ratio

3.69Industry Average 7.315.0Point

Lower than industry avg (good)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲7004.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼16.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -17.7% (declining, 3yr)

Detailed News Sentiment

5 totalPositive 5Neutral 0Negative 0Average Sentiment Score 85

Positive
박셀바이오, 전남대 화순 NIIC·GIST와 차세대 항암면역 국책과제 ...
박셀바이오가 전남대와 GIST와의 협력으로 차세대 항암면역 치료 플랫폼 개발에 착수하여 기술 혁신과 투자 확대 기대.
Positive
박셀, 'NK세포 대량증식' 기술 개발…학술지 게재
박셀바이오의 NK세포 대량증식 기술이 국제 학술지 게재를 통해 혁신적인 연구 성과를 인정받아 긍정적인 시장 반응 예상.
Positive
[클리니컬 히스토리] 박셀바이오, 치료전환 재신청 키 '세포 대량증식....
박셀바이오의 NK세포 대량증식 기술이 VAX-NK 치료제의 임상 재신청에 긍정적 영향을 미쳐 주가 상승 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 4,940Won52-week high 11,00052-week low 4,940

1-month return0.0Point

1m -29.63% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral기업설명회(IR)개최2026-05-18
Neutral분기보고서 (2026.03)2026-05-15